Brokerages predict that Epizyme Inc (NASDAQ:EPZM) will announce earnings of ($0.53) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Epizyme’s earnings. The lowest EPS estimate is ($0.61) and the highest is ($0.47). Epizyme reported earnings of ($0.42) per share during the same quarter last year, which would indicate a negative year over year growth rate of 26.2%. The business is expected to announce its next earnings results on Thursday, August 1st.
On average, analysts expect that Epizyme will report full-year earnings of ($2.00) per share for the current year, with EPS estimates ranging from ($2.35) to ($1.56). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.79) per share, with EPS estimates ranging from ($2.42) to ($0.80). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Epizyme.
Epizyme (NASDAQ:EPZM) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.07. The business had revenue of $7.89 million for the quarter, compared to analyst estimates of $1.13 million.
NASDAQ EPZM traded down $0.17 on Friday, reaching $12.68. 8,455 shares of the company’s stock traded hands, compared to its average volume of 1,129,224. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -7.37 and a beta of 2.73. The business has a 50 day moving average of $13.02. Epizyme has a fifty-two week low of $5.14 and a fifty-two week high of $16.59. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.55 and a current ratio of 12.55.
In other news, CEO Robert B. Bazemore sold 2,074 shares of the business’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $12.10, for a total transaction of $25,095.40. Following the completion of the sale, the chief executive officer now owns 87,068 shares of the company’s stock, valued at $1,053,522.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David M. Mott sold 104,944 shares of the business’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $13.08, for a total transaction of $1,372,667.52. Following the sale, the director now directly owns 13,979 shares of the company’s stock, valued at approximately $182,845.32. The disclosure for this sale can be found here. Insiders have sold 108,203 shares of company stock valued at $1,412,101 in the last three months. Corporate insiders own 16.60% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in EPZM. Legal & General Group Plc increased its stake in shares of Epizyme by 16.9% during the fourth quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,455 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in shares of Epizyme during the fourth quarter worth about $76,000. Exane Derivatives purchased a new stake in shares of Epizyme during the first quarter worth about $84,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Epizyme by 326.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,541 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 12,663 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Epizyme by 992.8% during the first quarter. BNP Paribas Arbitrage SA now owns 13,627 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 12,380 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Read More: Is it Safe to Invest in Commodities?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.